Back Bay Life Science Report

In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this year, “The Transactional Landscape of ADCs: A Payday for Payloads.” This conversation explores the dynamics and data within the emerging ADC field, including:
  • Background information on the class of therapeutics known as ADCs, which have been on the market since 2000
  • The number of headlines around ADCs lately, especially the standing ovation the data from Enhertu received at ASCO in 2022, making waves in breast cancer treatment
  • Deal structures and the BD side of ADCs, and their extended revenue generation potential
  • Where the field is headed, in terms of clinical, BD and commercial standpoints
Read and connect with our authors:  The Transactional Landscape Of ADCs: A Payday for Payloads

What is Back Bay Life Science Report?

Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.